We previously isolated BAL-EVs from patients with stable (CTRL), or chronic (CLAD) rejection, co-cultivated with HBEC recipient cells and analyzed secreted cytokines. Now, we characterized the origin of BAL-EV and integrated proteomic and transcriptomic data of HBEC exposed to BAL-EV to preliminary chart the lung microenvironment during early chronic lung allograft rejection (CLAD).
BAL-EVs from LungTransplanted Patients are of LeukocyticOrigin and Activates IL17 Pathway inRespiratory Cells / V. Vaira, A. Storaci, N. Mansour, S. Franzi, M. De Filippo, H. Eidgah, V. Musso, L. Morlacchi, L. Rossetti, F. Blasi, L. Rosso, M. Nosotti, S. Ferrero, A. Palleschi. ((Intervento presentato al 44. convegno ISHLT Annual Meeting & Scientific Sessions tenutosi a Praha nel 2024.
BAL-EVs from LungTransplanted Patients are of LeukocyticOrigin and Activates IL17 Pathway inRespiratory Cells
V. VairaPrimo
;A. StoraciSecondo
;L. Morlacchi;F. Blasi;L. Rosso;M. Nosotti;S. FerreroPenultimo
;A. PalleschiUltimo
2024
Abstract
We previously isolated BAL-EVs from patients with stable (CTRL), or chronic (CLAD) rejection, co-cultivated with HBEC recipient cells and analyzed secreted cytokines. Now, we characterized the origin of BAL-EV and integrated proteomic and transcriptomic data of HBEC exposed to BAL-EV to preliminary chart the lung microenvironment during early chronic lung allograft rejection (CLAD).
| File | Dimensione | Formato | |
|---|---|---|---|
|
ISHLT 2024 (BAL-EVs...).pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
191.07 kB
Formato
Adobe PDF
|
191.07 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
